---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-005563"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2025-02-10T23:59:59+00:00"
generated_at: "2026-05-27T00:08:48.700065+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Oncocyte raises $29.1M equity; Bio-Rad invests; funds transplant assay to FDA clearance

## Summary
- Gross proceeds of $29.1M from registered direct ($7.4M) and PIPE ($21.7M) offerings at $2.05/share.
- Five largest shareholders led round, including strategic partner Bio-Rad Laboratories (NYSE: BIO).
- Proceeds expected to fully fund FDA IVD clearance and commercial launch of proprietary transplant assay.
- Terminated at-the-market Sales Agreement with Needham; $1.8M previously sold under it.

## SEC filing metadata
- accession: 0001493152-25-005563
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2025-02-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315225005563/0001493152-25-005563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315225005563/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-005563
- JSON: https://secwatch.observer/filing/0001493152-25-005563.json
- Plain text: https://secwatch.observer/filing/0001493152-25-005563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.